NCT02348320View on ClinicalTrials.gov

Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 17, 2015

Primary Completion Date

March 12, 2020

Study Completion Date

March 12, 2020

Conditions
Triple Negative Breast CancerTriple-Negative Breast CancerTriple Negative Breast Neoplasms
Interventions
BIOLOGICAL

Personalized polyepitope DNA vaccine

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

Susan G. Komen Breast Cancer Foundation

OTHER

lead

Washington University School of Medicine

OTHER

NCT02348320 - Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy | Biotech Hunter | Biotech Hunter